CEPI awards up to US$21 million to Themis for Phase 3 Chikungunya Vaccine Development4. June 2019|In Portfolio News|By eazee-designstudioThemis and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a second partnering agreement under which CEPI, with support from the EU’s Horizon 2020 programme, will provide up to US$21 million of non-dilutive capital for Themis’ Phase 3-ready Chikungunya vaccine (MV-CHIK). The funding will underwrite a collaborative effort to accelerate regulatory approval of Themis’ Chikungunya vaccine and ensure that at-risk populations have access to the vaccine. PrevNext
